Denna sida på svenska

Sonia Lain

Professor

Visiting address : Nobels Väg 16 171 77 Stockholm, Sweden
Postal address : Department of Microbiology, Tumor and Cell Biology (MTC), C1, Sonia Lain group, Box 280 171 77 Stockholm, Sweden

Publications

Acetylation site specificities of lysine deacetylase inhibitors in human cells
Schölz C, Weinert Bt, Wagner Sa, Beli P, Miyake Y, Qi J, et al
Nature biotechnology 2015;33(4):415-23

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
Haaland I, Opsahl Ja, Berven Fs, Reikvam H, Fredly Hk, Haugse R, et al
MOLECULAR CANCER 2014;:116-

SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells
Li L, Osdal T, Ho Y, Chun S, Mcdonald T, Agarwal P, et al
Cell stem cell 2014;15(4):431-46

SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth
Ma L, Maruwge W, Strambi A, D'arcy P, Pellegrini P, Kis L, et al
Cell death & disease 2014;5():e1483-

Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6
Maccallum Sf, Groves Mj, James J, Murray K, Appleyard V, Prescott Ar, et al
SCIENTIFIC REPORTS 2013;:1275-

Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression
Sachweh Mc, Drummond Cj, Higgins M, Campbell J, Laín S
Cell death & disease 2013;4():e533-

Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2
Van Leeuwen Im, Higgins M, Campbell J, Mccarthy Ar, Sachweh Mc, Navarro Am, et al
Molecular cancer therapeutics 2013;12(4):471-80

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy
Rao B, Lain S, Thompson Am
BRITISH JOURNAL OF CANCER 2013;109(12):2954-8

Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner
Mccarthy Ar, Sachweh Mc, Higgins M, Campbell J, Drummond Cj, Van Leeuwen Im, et al
Molecular cancer therapeutics 2013;12(4):352-60

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells
Van Leeuwen Imm, Rao B, Sachweh Mcc, Lain S
CELL CYCLE 2012;11(9):1851-61

p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP
Madapura Hs, Salamon D, Wiman Kg, Lain S, Klein G, Klein E, et al
Cell cycle (Georgetown, Tex.) 2012;11(24):4563-9

Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins
Mccarthy Ar, Pirrie L, Hollick Jj, Ronseaux S, Campbell J, Higgins M, et al
BIOORGANIC & MEDICINAL CHEMISTRY 2012;20(5):1779-93

Mechanism-specific signatures for small-molecule p53 activators
Van Leeuwen Imm, Higgins M, Campbell J, Brown Cj, Mccarthy Ar, Pirrie L, et al
CELL CYCLE 2011;10(10):1590-8

N1-Benzyl substituted cambinol analogues as isozyme selective inhibitors of the sirtuin family of protein deacetylases
Medda F, Joseph Tl, Pirrie L, Higgins M, Slawin Amz, Lain S, et al
MEDCHEMCOMM 2011;2(7):611-615

Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs
Van Leeuwen Imm, Lain S
ONCOTARGET 2011;2(4):274-6

Drug discovery in the p53 field
Lain S
SEMINARS IN CANCER BIOLOGY 2010;20(1):1-2

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy
Rao B, Van Leeuwen Imm, Higgins M, Campbell J, Thompson Am, Lane Dp, et al
ONCOTARGET 2010;1(7):639-50

p53-based Cancer Therapy
Lane Dp, Cheok Cf, Lain S
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY 2010;2(9):a001222-

Awakening guardian angels: drugging the p53 pathway
Brown Cj, Lain S, Verma Cs, Fersht Ar, Lane Dp
NATURE REVIEWS CANCER 2009;9(12):862-73

Leptomycin B induces apoptosis in cells containing the whole HPV 16 genome
Jolly Ce, Gray Lj, Parish Jl, Lain S, Herrington Cs
INTERNATIONAL JOURNAL OF ONCOLOGY 2009;35(3):649-56

Novel Cambinol Analogs as Sirtuin Inhibitors: Synthesis, Biological Evaluation, and Rationalization of Activity
Medda F, Russell Rjm, Higgins M, Mccarthy Ar, Campbell J, Slawin Amz, et al
JOURNAL OF MEDICINAL CHEMISTRY 2009;52(9):2673-82

Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain
Yadavilli S, Mayo Ld, Higgins M, Lain S, Hegde V, Deutsch Wa
DNA REPAIR 2009;8(10):1215-24

Sirtuins and p53
Van Leeuwen I, Lain S
ADVANCES IN CANCER RESEARCH, VOL 102 2009;:171-95

Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen
Staples Od, Hollick Jj, Campbell J, Higgins M, Mccarthy Ar, Appleyard V, et al
CELL CYCLE 2008;7(21):3417-27

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator
Lain S, Hollick Jj, Campbell J, Staples Od, Higgins M, Aoubala M, et al
CANCER CELL 2008;13(5):454-63

If p53 can't do it, ask p73
Lain S
CELL CYCLE 2008;7(21):3290-3291

p53 as a therapeutic target
Staples Od, Steele Rjc, Lain S
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND 2008;6(4):240-3

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator
Lain S, Hollick J, Campbell J, Staples O, Higgins M, Mustapha A, et al
MOLECULAR CANCER THERAPEUTICS 2007;6(12):3476S-3477S

Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes
Gray Lj, Bjelogrlic P, Appleyard Vcl, Thompson Am, Jolly Ce, Lain S, et al
INTERNATIONAL JOURNAL OF CANCER 2007;120(11):2317-24

Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6
Camus S, Menendez S, Cheok Cf, Stevenson Lf, Lain S, Lane Dp
ONCOGENE 2007;26(28):4059-70

Activation of p53 by small molecules from fish to man
Lane D, Lain S
EJC SUPPLEMENTS 2006;4(12):75-75

Induction of apoptosis by leptomycin B in keratinocytes expressing HPV genes is mediated by high-risk E7 expression
Grey Lj, Bjelogrlic P, Jolly C, Macrobbie M, Thompson G, Lain S, et al
JOURNAL OF PATHOLOGY 2005;:38-38

P53 abnormalities and outcomes in colorectal cancer: a systematic review
Munro Aj, Lain S, Lane Dp
BRITISH JOURNAL OF CANCER 2005;92(3):434-44

Pilot screening programme for small molecule activators of p53
Berkson Rg, Hollick Jj, Westwood Nj, Woods Ja, Lane Dp, Lain S
INTERNATIONAL JOURNAL OF CANCER 2005;115(5):701-10

Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6
Camus S, Higgins M, Lane Dp, Lain S
FEBS LETTERS 2003;536(1-3):220-4

Improving cancer therapy by non-genotoxic activation of p53
Lain S, Lane D
EUROPEAN JOURNAL OF CANCER 2003;39(8):1053-60

Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein
Menendez S, Higgins M, Berkson Rg, Edling C, Lane Dp, Lain S
BRITISH JOURNAL OF CANCER 2003;88(4):636-43

Oligomerization of the human ARF tumor suppressor and its response to oxidative stress
Menendez S, Khan Z, Coomber Dw, Lane Dp, Higgins M, Koufali Mm, et al
JOURNAL OF BIOLOGICAL CHEMISTRY 2003;278(21):18720-9

Protecting p53 from degradation
Lain S
BIOCHEMICAL SOCIETY TRANSACTIONS 2003;:482-5

Therapeutic exploitation of the p53 pathway
Lane Dp, Lain S
TRENDS IN MOLECULAR MEDICINE 2002;8(4):S38-42

Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo
Xirodimas D, Saville Mk, Edling C, Lane Dp, Lain S
ONCOGENE 2001;20(36):4972-83

Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser(431) by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth
Sapkota Gp, Kieloch A, Lizcano Jm, Lain S, Arthur Jsc, Williams Mr, et al
JOURNAL OF BIOLOGICAL CHEMISTRY 2001;276(22):19469-82

Activation of p53 in cervical carcinoma cells by small molecules
Hietanen S, Lain S, Krausz E, Blattner C, Lane Dp
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2000;97(15):8501-6

Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation
Rodriguez Ms, Desterro Jmp, Lain S, Lane Dp, Hay Rt
MOLECULAR AND CELLULAR BIOLOGY 2000;20(22):8458-67

p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes
Paramio Jm, Segrelles C, Lain S, Gomez-casero E, Lane Dp, Lane Eb, et al
MOLECULAR CARCINOGENESIS 2000;29(4):251-62

Accumulating active p53 in the nucleus by inhibition of nuclear export: A novel strategy to promote the p53 tumor suppressor function
Lain S, Xirodimas D, Lane Dp
EXPERIMENTAL CELL RESEARCH 1999;253(2):315-24

An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs
Lain S, Midgley C, Sparks A, Lane Eb, Lane Dp
EXPERIMENTAL CELL RESEARCH 1999;248(2):457-72

Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B
Smart P, Lane Eb, Lane Dp, Midgley C, Vojtesek B, Lain S
ONCOGENE 1999;18(51):7378-86

SUMO-1 modification activates the transcriptional response of p53
Rodriguez Ms, Desterro Jmp, Lain S, Midgley Ca, Lane Dp, Hay Rt
EMBO JOURNAL 1999;18(22):6455-61

Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule
Fahraeus R, Lain S, Ball Kl, Lane Dp
ONCOGENE 1998;16(5):587-96

Differential expression and functionally co-operative roles for the retinoblastoma family of proteins in epidermal differentiation
Paramio Jm, Lain S, Segrelles C, Lane Eb, Jorcano Jl
ONCOGENE 1998;17(8):949-57

Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21(WAF1)
Ball Kl, Lain S, Fahraeus R, Smythe C, Lane Dp
CURRENT BIOLOGY 1997;7(1):71-80

Inhibition of pRb phosphorylation and cell cycle progression by an p16(INK4a) derived synthetic peptide designed for intracellular delivery
Fahraeus R, Paramio Jm, Ball Kl, Lain S, Lane Dp
CANCER GENE THERAPY 1997;4(1):66-67

Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16(CDKN2/INK4A)
Fahraeus R, Paramio Jm, Ball Kl, Lain S, Lane Dp
CURRENT BIOLOGY 1996;6(1):84-91

PU BOX-BINDING TRANSCRIPTION FACTORS AND A POU DOMAIN PROTEIN COOPERATE IN THE EPSTEIN-BARR-VIRUS (EBV) NUCLEAR-ANTIGEN-2-INDUCED TRANSACTIVATION OF THE EBV LATENT-MEMBRANE-PROTEIN-1 PROMOTER
Sjoblom A, Jansson A, Yang Ww, Lain S, Nilsson T, Rymo L
JOURNAL OF GENERAL VIROLOGY 1995;:2679-92

RNA HELICASE ACTIVITY OF THE PLUM POX POTYVIRUS CL PROTEIN EXPRESSED IN ESCHERICHIA-COLI - MAPPING OF AN RNA-BINDING DOMAIN
Fernandez A, Lain S, Garcia Ja
NUCLEIC ACIDS RESEARCH 1995;23(8):1327-32

Show all publications